Upstream Bio (UPB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO, with board members, management, and independent auditor present.
Meeting conducted virtually in accordance with bylaws and Delaware law.
Rules of conduct and voting eligibility outlined; only stockholders of record as of April 13, 2026, or their proxies, may participate.
Board and executive committee updates
Two nominees, Edd Fleming and Liam Ratcliffe, were nominated for Class II director positions for three-year terms.
No stockholder nominations for directors were received in advance.
Shareholder proposals
Election of two Class II directors and ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026, were the main proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Upstream Bio
- Quarterly dosing with verekitug shows best-in-class efficacy in asthma and CRSwNP, phase III next year.UPB
Goldman Sachs 47th Annual Global Healthcare Conference 202610 Jun 2026 - Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for major respiratory diseases.UPB
Corporate presentation13 May 2026 - Phase 3 trials in severe asthma and CRSwNP set for Q1 2027, with cash runway through 2027.UPB
Q1 202613 May 2026 - Verekitug cut severe asthma exacerbations by 56% and improved lung function with strong safety.UPB
Study result20 Apr 2026 - Vote on two director elections and auditor ratification at the June 2026 virtual meeting.UPB
Proxy filing16 Apr 2026 - Virtual meeting to elect directors, ratify auditor, and reinforce governance and oversight.UPB
Proxy filing16 Apr 2026 - Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027.UPB
Corporate presentation8 Apr 2026 - Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027.UPB
Corporate presentation26 Mar 2026 - Strong Phase 2 results and robust cash position support a high-dose quarterly Phase 3 strategy.UPB
Q4 202526 Mar 2026